Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 8:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 2,241 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: RNA sequencing Clear all
Terminated Phase 2 Interventional Results available

Study to Evaluate the Effects of MEDI6012 on Apolipoprotein B100 Metabolism

NCT03773172
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
MEDI6012, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
35 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 18, 2026, 8:09 AM EDT
Completed No phase listed Observational Results available

Testing the Effectiveness of WW Clinic GLP1

NCT06034457
View directory record Official record
Conditions
Weight Loss, Obesity
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 18, 2026, 8:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Staccato® Granisetron Single Dose PK

NCT04200092
View directory record Official record
Conditions
Healthy
Interventions
0.5mg AZ-010; placebo, 1mg AZ-010, 3mg AZ-010, AZ-010 1mg, IV Granisetron 1mg, Placebo
Combination Product · Drug · Other
Lead sponsor
Nova Pneuma Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 18, 2026, 8:09 AM EDT
Completed Phase 1 Interventional

Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC

NCT04610671
View directory record Official record
Conditions
Muscle-Invasive Bladder Carcinoma, Bladder Cancer
Interventions
CG0070, Nivolumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 18, 2026, 8:09 AM EDT
Completed Phase 4 Interventional Results available

Effect of High and Low Sodium Diets on Blood Pressure in Hypertensive Patients Treated With Aliskiren

NCT00441064
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 60 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
19
States / cities
Orangevale, California • Brooklyn Center, Minnesota • Butte, Montana + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2011 · Synced Oct 18, 2026, 8:09 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM

NCT02766699
View directory record Official record
Conditions
Glioblastoma, Astrocytoma, Grade IV
Interventions
EGFR(V)-EDV-Dox
Drug
Lead sponsor
Engeneic Pty Limited
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 18, 2026, 8:09 AM EDT
Completed No phase listed Observational

Trichomoniasis: Genotype and Phenotype Correlations in African American Women

NCT00998530
View directory record Official record
Conditions
Trichomonas Infections
Interventions
Not listed
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
4
States / cities
Flowood, Mississippi • Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated May 23, 2019 · Synced Oct 18, 2026, 8:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Functional Magnetic Resonance Imaging (fMRI) in Patients Who Speak Two Languages Fluently

NCT03496181
View directory record Official record
Conditions
Glioma, Glioma of Brain, Glioma of Spinal Cord
Interventions
Multilingual Aphasia Examination, Language paradigms + RS fMRI, Language paradigms + RS fMRI + one anatomical sequence
Behavioral · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 18, 2026, 8:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Objective Vision Evaluation of Two Cosmetic Contact Lenses

NCT04287036
View directory record Official record
Conditions
Visual Acuity
Interventions
JJVC Investigational Contact Lens, 1-DAY ACUVUE® DEFINE® Radiant Sweet™
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 39 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 18, 2026, 8:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers

NCT02224053
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Pharmacokinetic sampling - AZD9291, AZD9291 tablet dosing, Omeprazole tablet dosing, Pharmacokinetic sampling - AZ5140 and AZ7550
Procedure · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Overland Park, Kansas • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2016 · Synced Oct 18, 2026, 8:09 AM EDT
Active, not recruiting Phase 2 Interventional

Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)

NCT04938609
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Interventions
Pembrolizumab, Stereotactic Body Radiation Therapy (5 days), Surgical Resection
Drug · Radiation · Procedure
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
3
States / cities
San Diego, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 18, 2026, 8:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)

NCT06299709
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VNZ/TEZ/D-IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 18, 2026, 8:09 AM EDT
Terminated Phase 2 Interventional Results available

Individualizing Anti-Inflammatory Medications for Adults With Axial Spondyloarthritis: A Series of N-of 1 Trials

NCT04115098
View directory record Official record
Conditions
Axial Spondyloarthritis
Interventions
Celecoxib, Naproxen, Meloxicam
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Oct 18, 2026, 8:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Cardiac Effects of ALXN1840 in Healthy Adults

NCT04560816
View directory record Official record
Conditions
Healthy
Interventions
ALXN1840, Placebo, Moxifloxacin
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 18, 2026, 8:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation II

NCT05333107
View directory record Official record
Conditions
Healthy Volunteers; High Cholesterol
Interventions
NNC0385-0434 G, NNC0385-0434 F, NNC0385-0434 B
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Cypress, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 18, 2026, 8:09 AM EDT
Completed Not applicable Interventional Results available

Evaluation of Etomidate on Adrenal Function in Trauma Patients

NCT00462644
View directory record Official record
Conditions
Adrenal Insufficiency
Interventions
RSI sedation with etomidate/succinylcholine, RSI sedation with fentanyl/midazolam/succinylcholine
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 23, 2010 · Synced Oct 18, 2026, 8:09 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Investigating Near-Threshold Perception During Ultrasonic Deep Brain Stimulation

NCT07840521
View directory record Official record
Conditions
Consciousness, Level Altered
Interventions
Low-intensity focused ultrasound pulsation (LIFUP), Functional Magnetic Resonance Imaging (fMRI), Magnetic Resonance Spectroscopy, Multi-modal glymphatic function MRI
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 40 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2032
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 18, 2026, 8:09 AM EDT
Recruiting Not applicable Interventional

Transcranial Magnetic Stimulation for MCI

NCT05992831
View directory record Official record
Conditions
Mild Cognitive Impairment, Depression
Interventions
Accelerated iTBS, Sham Comparator
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
60 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 18, 2026, 8:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Canagliflozin and Metformin Immediate Release (50 mg/500 mg) FDC Tablets in Healthy Volunteers

NCT01508195
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin tablets, Metformin IR tablets, Canagliflozin/metformin IR FDC tablets
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 18, 2026, 8:09 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Abdominal MR Imaging at 3.0T: Sequence Optimization and Implementation

NCT01007357
View directory record Official record
Conditions
Diffuse and Focal Abnormalities of the Liver and Pancreas
Interventions
Body MR imaging
Device
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
2
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 14, 2023 · Synced Oct 18, 2026, 8:09 AM EDT
Completed Phase 1 Interventional

A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis

NCT02965053
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
EOS789, Placebo, Renvela
Drug
Lead sponsor
Chugai Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Oct 18, 2026, 8:09 AM EDT
Completed Phase 1Phase 2 Interventional Results available

First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221

NCT02675465
View directory record Official record
Conditions
Pompe Disease
Interventions
ATB200, AT2221
Drug
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
12
States / cities
Phoenix, Arizona • Orange, California • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 18, 2026, 8:09 AM EDT
Completed No phase listed Observational

Identify Predictors That Distinguish Between Tofacitinib Responders and Non-responders Based on Genotype and Cellular and Molecular Profiles From Pinch Biopsies, Blood and Stool Samples

NCT03663400
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
GWAS analysis by Illumina BeadChip
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2022 · Synced Oct 18, 2026, 8:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Tasimelteon Alone and in Combination With CYP1A2 Inhibitor, Fluvoxamine

NCT01540500
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Tasimelteon, Fluvoxamine
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 17, 2014 · Synced Oct 18, 2026, 8:09 AM EDT